Aurealis Therapeutics

Aurealis Therapeutics is a Swiss-Nordic Cell & Gene Therapy Platform Company. Our multi-target platform, based on genetically modified safe lactic acid bacteria, addresses unmet medical needs: Chronic Wounds - Diabetic Foot Ulcers, Venous Ulcers, Pressure Ulcers - deadly Cancers - Ovarian Cancer, Peritoneal Carcinomatosis - Inflammation.
After completing a Phase 1 clinical study in Diabetic Foot Ulcer (DFU) patients with our lead product AUP-16, we are initiating a DFU Phase 2 study in Italy, Germany and Poland. Venous Ulcers and Pressure Ulcers will follow.
In Oncology, we are building on impressive survival data with Bacterial Vector lead candidate AUP-55 in Ovarian Cancer